WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices. The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court. |
The past continues to shape our futureChina launches experimental satellites to advance 6G techXi Urges Ceasefire in Gaza, Stresses TwoExperiencing traditional crafts at China International Fair for Trade in ServicesCPC Leadership Holds Meeting on 2024 Economic Work, AntiEthnic minority students participated in a fun campus game to welcome the Asian GamesSolving problems togetherXi Sends Congratulatory Letter to 2023 Imperial Springs Int'l ForumXi Inspects Exhibition on Shanghai's SciXi, Uruguayan President Hold Talks, Elevate Ties to Comprehensive Strategic Partnership